Effect of once, twice, or thrice weekly administration of intravenous levocarnitine in the treatment of patients with carnitine deficiency undergoing hemodialysis: a retrospective observational study.

Effect of once, twice, or thrice weekly administration of intravenous levocarnitine in the treatment of patients with carnitine deficiency undergoing hemodialysis: a retrospective observational study. - Effect of levocarnitine on hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039353

Enrollment

100

Registered

2020-02-01

Start date

2020-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with carnitine deficiency undergoing hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We compared the effects of levocarnitine administration at several frequencies in the treatment of carnitine-deficiency patients with renal anemia undergoing HD, through the measurement of total carnitine (TC) and free carnitine (FC) serum levels.

Exclusion criteria

Exclusion criteria: The study excluded patients who (1) had previously received oral or IV levocarnitine; (2) had received any carnitine supplement; (3) had difficulty communicating due to dementia or other factors; (4) had acute inflammation; (5) had received immunosuppressants, steroids, or antibiotics; and (6) had received blood transfusion in the past 6 months.

Design outcomes

Primary

Measure	Time frame
renal anemia	—

Secondary

Measure	Time frame
total carnitine, free carnitine serum levels,hypotension, cardiac insufficiency, and muscle weakness. the required ESA	—

Countries

Japan

Contacts

Public ContactShohei Sawada

Ijinkai General Takeda Hospital, Division of Nephrology & Hemodialysis, Hemodialysis Center,

shoheisawada@yahoo.co.jp075-572-6331

Outcome results